top of page

Argentina Clears Engineered Bacterium to Make Animal Feed Enzyme

Writer: AgriLinkage Technology
AgriLinkage Technology
2 hours ago
4 min read

Argentina has authorized an engineered strain of Bacillus subtilis for contained industrial production of a protease enzyme used mainly in animal nutrition, opening a new regulatory route for agricultural biotechnology beyond genetically modified crops.


The Agriculture, Livestock and Fisheries Secretariat published Resolution 233/2026 on 18 November. The measure, signed on 16 November, permits Danisco Argentina to commercialize Bacillus subtilis AP514 for its declared use in controlled fermentation. The authorization is for the production process and its enzyme output. It is not an approval to release the modified bacterium into fields or to place viable modified cells directly into animal feed.



What Argentina actually approved


The strain is used inside an industrial fermenter to produce protease. Proteases break proteins into smaller peptides and amino acids. In animal nutrition they can be added to some feed formulations to help make dietary protein more available, although results depend on the animal species, feed ingredients, dose and production conditions.


Argentina’s National Advisory Commission on Agricultural Biotechnology, known as CONABIA, assessed the declared contained use. According to the resolution, the commission concluded that use of AP514 in authorized production plants did not add risk to the agroecosystem when compared with the nonmodified counterpart. It also accepted the submitted validation of biomass inactivation and the evidence used to determine that no viable modified microorganisms remained in the final product.


A separate government summary of the decision says the final genome contains neither antibiotic resistance genes nor bacterial vector sequences. It says the modifications are not expected to increase pathogenicity, toxin production, survival or environmental impact for the declared industrial use.


Those findings answer a specific biosafety question. They do not prove that the enzyme improves feed conversion, growth, animal health or farm profit in every ration. The public documents do not disclose the intended animal species, commercial dose, manufacturing volume, launch date or price. Any performance claim will need product specific evidence and must comply with the rules applied by Argentina’s food and animal health authorities.


A faster review built around the proposed use


The case is the first product that Argentina says entered and completed the prior consultation mechanism created under Resolution 255/2026. That framework allows regulators to decide which assessments are necessary after examining the organism, the proposed use and the final product.


For this application, officials determined that only the agroecosystem risk assessment by CONABIA was required. The enzyme solution is made through controlled fermentation, and the submitted process was designed to remove viable modified cells. The government says the evaluation and commercial authorization took three months.


The speed is commercially important because microbial strains can be tailored to manufacture enzymes, amino acids and other inputs used across feed and food processing. A review that focuses on the actual exposure pathway may lower regulatory time and cost for contained production. It may also make Argentina a more attractive location for industrial biotechnology investment.


One approval, however, does not establish how quickly later cases will move. Different organisms, live microbial products, uses involving environmental release or final products containing viable cells could require broader assessments. Resolution 255 keeps a case by case approach, and Argentina can require reviews of food or feed suitability and market impacts where those questions are relevant.


Why the decision matters for feed production


Feed manufacturers try to balance animal performance with the cost and variability of protein ingredients such as soybean meal. Enzymes can help formulators use nutrients more efficiently, but the value of any enzyme depends on the surrounding ration and on evidence from the target species. Regulatory clearance removes one barrier to production. It does not remove the need for formulation trials, quality control and commercial comparison with existing products.


The decision also broadens the public meaning of agricultural biotechnology in Argentina. The country is already a major user and exporter of genetically modified crops. This authorization applies the system to a microbial production platform operating inside a factory, where the main regulatory questions are containment, inactivation and the characteristics of the final enzyme product.


What happens next


Resolution 233 requires Danisco Argentina to provide regulators immediately with any new scientific information that could undermine the conclusions supporting the authorization. The government can cancel the approval if new evidence invalidates those conclusions. The resolution also directs the company to comply with the rules of other competent control bodies and sends the decision to the national food and animal health service, SENASA, for its role.


The next indicators are practical ones: whether the enzyme receives any additional product approvals needed for sale, where and at what scale it is manufactured, which animal markets it targets, and whether independent or disclosed commercial trials show a measurable benefit under Argentine feeding conditions.


Methodology and sources


Agrilinkage reviewed the full text of Resolution 233/2026, the Agriculture Secretariat’s announcement dated 18 November 2026 and the regulatory framework in Resolution 255/2026. The article distinguishes the regulator’s biosafety findings from performance claims that were not established in the public decision. No interviews or firsthand facility observations were conducted.

Comments


bottom of page